Dedicated to the discovery and development of innovative therapeutics for Neurological Disorders by targeting a novel signaling pathway. 
Novel Mechanism of Action
Rejuvenating the Brain by Reversing Synaptic Loss
Clinical Stage Development 
Neurodegenerative Disease and Psychiatric Disorder - Focused Pipeline

Indication

Phase II a

Phase II b

Phase III

Alzheimer's Disease:  

Anxiety/Sleep

Depression

Active

Complete

Complete

Complete

Concussion

Schizophrenia

Complete

Active

Planned

Planned

Planned

Planned

Neurocentria, Inc.

1855 Olympic Blvd., Ste. 225 Walnut Creek, CA., U.S.A.  94596

info@neurocentria.com

925-954-4868

2018 Neurocentria, Inc.